Know Cancer

or
forgot password

Magnetic Resonance Correlates of Glioma Tumor Burden


N/A
18 Years
N/A
Not Enrolling
Both
Brain and Central Nervous System Tumors

Thank you

Trial Information

Magnetic Resonance Correlates of Glioma Tumor Burden


OBJECTIVES: I. Determine whether proton magnetic resonance spectroscopic imaging (1H-MRSI)
and diffusion magnetic resonance imaging (DI) measures of glioma cell burden correlate with
histopathologically measured cell counts in glioma patients who are scheduled to undergo
surgical resection. II. Determine whether 1H-MRSI and DI measures of glioma cell burden are
invariant over the short term (1 week) as steroid dose is increased in these patients.

OUTLINE: Part I: Patients who are scheduled to have surgical resection of brain tumor
undergo conventional magnetic resonance imaging (MRI), proton magnetic resonance
spectroscopic imaging (1H-MRSI), and diffusion magnetic resonance imaging (DI) within 1 week
before resection. Patients undergo conventional MRI within 72 hours after completion of
surgical resection. Image characteristics of the resected tissue are correlated with
histopathological measures. Part II: Patients who have clinical indications for increasing
the dexamethasone dose are treated on part II of the study. Patients are stratified by
status of steroid treatment (steroid naive vs prior steroid management). Patients undergo
conventional MRI, 1H-MRSI, and DI within 2 days before and within 4-7 days after increasing
the dexamethasone dose. Image characteristics on films taken before and after increasing the
dexamethasone dose are compared.

PROJECTED ACCRUAL: A total of 75 patients will be accrued for part I of the study and a
total 40 patients (20 per stratum) will be accrued for part II of the study within 4 years.

Inclusion Criteria


DISEASE CHARACTERISTICS: Part I: Presurgical: presumptive diagnosis of intracranial glioma
and scheduled to undergo first surgical resection OR stereotactic biopsy Postsurgical:
Histologically proven intracranial glioma and scheduled to undergo surgical debulking
Evaluable preoperative proton magnetic resonance spectroscopic imaging (1H-MRSI) and
diffusion magnetic resonance imaging (DI) scans completed within 1 week prior to surgery
Postoperative MRI, 1H-MRSI, and DI scans completed within 3 days after surgery Part II:
Presurgical: presumptive diagnosis of intracranial glioma Postsurgical: Histologically
proven intracranial glioma No surgery prior to completion of exit scans Clinical
indication for increasing steroid dose Planned steroid changes must be from 0 to 16 mg/day
or a twofold increase Evaluable 1H-MRSI and DI scans No prior treatment on this protocol
Parts I and II: No contraindications for magnetic resonance imaging (MRI) (metallic
implants, shrapnel fragments, claustrophobia, allergy to MRI contrast)

PATIENT CHARACTERISTICS: Age: Parts I and II: Over 18 Performance status: Parts I and II:
Not specified Life expectancy: Parts I and II: Not specified Hematopoietic: Parts I and
II: Not specified Hepatic: Parts I and II: Not specified Renal: Parts I and II: Not
specified

PRIOR CONCURRENT THERAPY: Biologic therapy: Parts I and II: Not specified Chemotherapy:
Parts I and II: Not specified Endocrine therapy: Part I: Not specified Part II: Steroid
naive or prior steroid management allowed Radiotherapy: Parts I and II: See Disease
Characteristics Surgery: Part I: See Disease Characteristics No information from more than
2 surgeries from any one patient Part II: See Disease Characteristics

Type of Study:

Interventional

Study Design:

Primary Purpose: Diagnostic

Principal Investigator

Jeffry Alger, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Jonsson Comprehensive Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000067691

NCT ID:

NCT00005082

Start Date:

November 1998

Completion Date:

Related Keywords:

  • Brain and Central Nervous System Tumors
  • adult medulloblastoma
  • adult glioblastoma
  • adult anaplastic astrocytoma
  • adult myxopapillary ependymoma
  • adult anaplastic ependymoma
  • adult anaplastic oligodendroglioma
  • adult mixed glioma
  • adult pilocytic astrocytoma
  • adult subependymoma
  • adult ependymoblastoma
  • adult oligodendroglioma
  • adult giant cell glioblastoma
  • adult gliosarcoma
  • Glioma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms

Name

Location
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781